Endogenous IGF-I protects human intestinal smooth muscle cells from apoptosis by regulation of GSK-3β activity
Open Access
- 1 January 2005
- journal article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 288 (1) , G101-G110
- https://doi.org/10.1152/ajpgi.00032.2004
Abstract
We have previously shown that endogenous IGF-I regulates human intestinal smooth muscle cell proliferation by activation of phosphatidylinositol 3 (PI3)-kinase- and Erk1/2-dependent pathways that jointly regulate cell cycle progression and cell division. Whereas insulin-like growth factor-I (IGF-I) stimulates PI3-kinase-dependent activation of Akt, expression of a kinase-inactive Akt did not alter IGF-I-stimulated proliferation. In other cell types, Akt-dependent phosphorylation of glycogen synthase kinase-3β (GSK-3β) inhibits its activity and its ability to stimulate apoptosis. The aim of the present study was to determine whether endogenous IGF-I regulates Akt-dependent GSK-3β phosphorylation and activity and whether it regulates apoptosis in human intestinal muscle cells. IGF-I elicited time- and concentration-dependent GSK-3β phosphorylation (inactivation) that was measured by Western blot analysis using a phospho-specific GSK-3β antibody. Endogenous IGF-I stimulated GSK-3β phosphorylation and inhibited GSK-3β activity (measured by in vitro kinase assay) in these cells. IGF-I-dependent GSK-3β phosphorylation and the resulting GSK-3β inactivation were mediated by activation of a PI3-kinase-dependent, phosphoinositide-dependent kinase-1 (PDK-1)-dependent, and Akt-dependent mechanism. Deprivation of serum induced β-catenin phosphorylation, increased in caspase 3 activity, and induced apoptosis of muscle cells, which was inhibited by either IGF-I or a GSK-3β inhibitor. Endogenous IGF-I inhibited β-catenin phosphorylation, caspase 3 activation, and apoptosis induced by serum deprivation. IGF-I-dependent inhibition of apoptosis, similar to GSK-3β activity, was mediated by a PI3-kinase-, PDK-1-, and Akt-dependent mechanism. We conclude that endogenous IGF-I exerts two distinct but complementary effects on intestinal smooth muscle cell growth: it stimulates proliferation and inhibits apoptosis. The growth of intestinal smooth muscle cells is regulated jointly by the net effect of these two processes.Keywords
This publication has 38 references indexed in Scilit:
- IGFBP-3 activates TGF-β receptors and directly inhibits growth in human intestinal smooth muscle cellsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2004
- IGF-I stimulates human intestinal smooth muscle cell growth by regulation of G1phase cell cycle proteinsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2004
- Alleviating the Suppression of Glycogen Synthase Kinase-3β by Akt Leads to the Phosphorylation of cAMP-response Element-binding Protein and Its Transactivation in Intact Cell NucleiPublished by Elsevier ,2003
- Enhanced Glycogen Synthase Kinase-3β Activity Mediates Hypoxia-induced Apoptosis of Vascular Smooth Muscle Cells and Is Prevented by Glucose Transport and MetabolismJournal of Biological Chemistry, 2002
- Regulation of TRAIL Expression by the Phosphatidylinositol 3-Kinase/Akt/GSK-3 Pathway in Human Colon Cancer CellsJournal of Biological Chemistry, 2002
- Glycogen Synthase Kinase-3βCirculation Research, 2002
- GSK‐3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and β‐catenin stabilisation without elevation of glycogen synthase activityFEBS Letters, 2001
- Disruption of 3-Phosphoinositide-dependent Kinase 1 (PDK1) Signaling by the Anti-tumorigenic and Anti-proliferative AgentN-α-tosyl-l-phenylalanyl Chloromethyl KetonePublished by Elsevier ,2001
- Differential Expression and Localization of IGF-I and IGF Binding Proteins in Inflamed Rat ColonJournal of Receptors and Signal Transduction, 1998
- Targeted overexpression of IGF-I evokes distinct patterns of organ remodeling in smooth muscle cell tissue beds of transgenic mice.Journal of Clinical Investigation, 1997